Sanders Morris Harris LLC bought a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 4,970 shares of the company’s stock, valued at approximately $699,000.
A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Norges Bank purchased a new position in Johnson & Johnson in the fourth quarter valued at $4,139,107,000. Capital World Investors increased its stake in Johnson & Johnson by 182.9% during the 1st quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after buying an additional 13,703,905 shares during the period. Wellington Management Group LLP increased its stake in Johnson & Johnson by 10.8% during the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock worth $4,006,895,000 after buying an additional 2,968,879 shares during the period. Massachusetts Financial Services Co. MA increased its position in shares of Johnson & Johnson by 7.7% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock valued at $3,871,753,000 after purchasing an additional 2,118,870 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. increased its position in shares of Johnson & Johnson by 77.4% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 4,725,664 shares of the company’s stock valued at $689,332,000 after purchasing an additional 2,061,958 shares during the last quarter. Institutional investors and hedge funds own 68.51% of the company’s stock.
Several research analysts have recently issued reports on the stock. Stifel Nicolaus upped their target price on shares of Johnson & Johnson from $140.00 to $155.00 and gave the company a “hold” rating in a report on Wednesday, April 15th. Argus restated a “buy” rating and set a $155.00 price objective (down previously from $165.00) on shares of Johnson & Johnson in a research report on Friday, March 27th. Raymond James increased their price target on shares of Johnson & Johnson from $153.00 to $157.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. UBS Group downgraded shares of Johnson & Johnson from a “buy” rating to a “neutral” rating and cut their price target for the company from $163.00 to $160.00 in a report on Tuesday, April 28th. Finally, Wells Fargo & Co upgraded shares of Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $162.93.
Shares of JNJ traded down $0.02 during mid-day trading on Thursday, reaching $143.25. 781,722 shares of the stock traded hands, compared to its average volume of 7,245,217. The firm has a market cap of $377.46 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 3.11 and a beta of 0.69. The stock has a fifty day simple moving average of $143.95 and a 200 day simple moving average of $143.96. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The company has a quick ratio of 1.05, a current ratio of 1.31 and a debt-to-equity ratio of 0.41.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.30 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.27. The business had revenue of $20.69 billion during the quarter, compared to the consensus estimate of $19.48 billion. Johnson & Johnson had a net margin of 24.47% and a return on equity of 39.71%. The company’s quarterly revenue was up 3.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.10 earnings per share. On average, equities research analysts expect that Johnson & Johnson will post 7.7 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th were given a dividend of $1.01 per share. The ex-dividend date was Friday, May 22nd. This represents a $4.04 dividend on an annualized basis and a yield of 2.82%. This is a boost from Johnson & Johnson’s previous quarterly dividend of $0.95. Johnson & Johnson’s dividend payout ratio is presently 46.54%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Read More: Growth and Income Funds
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.